1. The list of vaccination sites for the Sisonke phase 3b study is attached;
2. The vaccine has not been study in children hence we are not sure about the efficacy and safety of these vaccines in children;
3. We have good evidence from clinical trials to support the efficacy of the Johnson&Johnson vaccine against the 501Y.V2 variant. In vitro studies suggest that the Pfizer and Moderna vaccines are effective as well against the 501Y.V2. We are awaiting the data relating to the effectiveness of the Sinopharm, Sinovac and Sputnik V vaccines against the 501Y.V2. In terms of Astra Zeneca and Novovax the studies to date suggest these vaccines have diminished effectiveness and the Ministerial Advisory Committee does not support the use of these vaccines at this stage.
END.